Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Holdings Raised by LSV Asset Management

LSV Asset Management increased its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 75.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 131,800 shares of the specialty pharmaceutical company’s stock after purchasing an additional 56,500 shares during the quarter. LSV Asset Management owned 0.40% of Collegium Pharmaceutical worth $4,057,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. raised its stake in Collegium Pharmaceutical by 320.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock worth $116,000 after acquiring an additional 2,877 shares during the period. Versor Investments LP bought a new stake in shares of Collegium Pharmaceutical in the 3rd quarter worth approximately $207,000. SG Americas Securities LLC acquired a new position in Collegium Pharmaceutical during the 3rd quarter valued at about $221,000. O Shaughnessy Asset Management LLC grew its holdings in Collegium Pharmaceutical by 14.3% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 11,509 shares of the specialty pharmaceutical company’s stock worth $257,000 after buying an additional 1,440 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Collegium Pharmaceutical by 28.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,841 shares of the specialty pharmaceutical company’s stock worth $272,000 after purchasing an additional 1,967 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a research note on Friday, February 23rd. Truist Financial lifted their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, February 26th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 price target on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $38.06 on Thursday. The company has a 50-day moving average of $37.61 and a two-hundred day moving average of $32.17. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 32.25 and a beta of 1.06. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10. Collegium Pharmaceutical, Inc. has a one year low of $20.83 and a one year high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.25. The company had revenue of $149.75 million for the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. On average, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.